Human induced pluripotent stem cells (hiPSCs) are developed as a therapeutic agent for treating patients with cardiovascular disease. The first disease target indication is peripheral arterial disease (PAD), which affects 8 – 1.2 million people in the US, typically over the age of 55 years, and results in chronic pain and ulceration. Critical limb ischemia (CLI) is the second target disease indication for this therapy. CLI affects 800,000 to 1 million patients in the US. Up to half of CLI patients undergo amputations within one year. Other potential diseases that would benefit from blood vessel growth or vasculogenesis include ischemic heart disease, diabetic retinopathy, diabetic neuropathy, and wound healing.